Drug Profile
Glucose/Glucose oxidase - Karo Pharma
Alternative Names: Glucose oxidase and glucose -Karo Pharma; T268A cold sprayLatest Information Update: 08 Oct 2021
Price :
$50
*
At a glance
- Originator Tanomed; Umea University
- Developer Karo Pharma AB
- Class Antibacterials; Antihypoglycaemics; Antivirals; Carbohydrates; Glucose oxidases; Hexoses
- Mechanism of Action Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Common cold
Most Recent Events
- 08 Oct 2021 No development reported - Phase-II for Common cold (In adults) in Sweden (Intranasal) (Karo Pharma website, October 2021)
- 08 Oct 2021 No development reported - Phase-II for Common cold (In children, In infants) in Sweden (Intranasal) (Karo Pharma website, October 2021)
- 04 Aug 2017 Phase II development is ongoing for Common cold (In infants, In children, In adults) in Sweden (Karo Pharma website, August 2017)